Tricida to Participate in Cowen 42nd Annual Health Care Conference
01 Março 2022 - 03:30PM
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused
on the development and commercialization of its investigational
drug candidate, veverimer, a non-absorbed, orally-administered
polymer designed to slow chronic kidney disease (CKD) progression
in patients with metabolic acidosis and CKD, announced today that
it will participate in a Kidney Disease / Fibrosis panel discussion
at the Cowen 42nd Annual Health Care Conference on Wednesday, March
9, 2022 at 11:10 am PT / 2:10 pm ET.
A live webcast of the panel discussion will be accessible on the
Tricida website at IR.Tricida.com. An archive of the webcast will
be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its investigational drug
candidate, veverimer, a non-absorbed, orally-administered polymer
designed to slow CKD progression in patients with metabolic
acidosis and CKD. Tricida is currently conducting a renal outcomes
clinical trial, VALOR-CKD, to determine if veverimer slows CKD
progression in patients with metabolic acidosis associated with
CKD. Metabolic acidosis is a condition commonly caused by CKD that
is believed to accelerate the progression of kidney deterioration.
There are currently no therapies approved by the FDA to slow
progression of kidney disease through the treatment of chronic
metabolic acidosis in patients with CKD. It is estimated to pose a
health risk to approximately three million patients with CKD in the
United States.
For more information about Tricida, please
visit www.Tricida.com.
Contact: Jackie Cossmon, IRCTricida, Inc.Vice President of
Investor Relations and CommunicationsIR@Tricida.com
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024
Notícias em tempo-real sobre Tricida Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de